Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

Vascular dementia is the second-most common form of dementia after Alzheimer’s. About 2.7 million people in the U.S. are ...

Two large-scale phase 3 trials found that semaglutide did not significantly slow cognitive decline in early-stage Alzheimer’s ...

Diabetes and weight loss drug semaglutide has been trialled in people with Alzheimer's. We explain what it means for dementia ...

A large study suggests that semaglutide may not slow early Alzheimer’s symptoms, though researchers say important clues ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

(CN) — An analysis of nearly 1.7 million patient records suggests that semaglutide — the active ingredient in popular diabetes and weight loss medications like Ozempic and Wegovy — may significantly ...

"While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer's disease, the extensive body of ...

A new study involving nearly 1.7 million patients suggests that semaglutide — a drug that mimics a gut hormone to lower blood sugar and aid weight loss — could significantly cut dementia risk in older ...

There are several risk factors for dementia, including type 2 diabetes and obesity. A new study reports that semaglutide — the active ingredient in GLP-1 medications Ozempic and Wegovy for type 2 ...

Medications commonly used to treat dementia could result in harmful weight loss, according to UC San Francisco researchers, and clinicians need to account for this risk when prescribing these drugs to ...